MedCity News July 19, 2024
Harvard spinout GRO Biosciences has a platform technology for engineering therapeutic proteins that won’t prompt an immune response against them. The startup’s lead program is a potential competitor to an Amgen gout drug acquired in a multi-billion dollar deal.
For gout pain that does not respond to conventional therapies, patients’ only remaining option is a drug from Amgen. But this biologic medicine introduces the same problem facing every therapeutic protein: The body can see the engineered protein as foreign, prompting an immune response that renders the treatment ineffective. The technology of GRO Biosciences engineers proteins that the immune system sees as belonging to the body. The biotech startup aims to overcome the immune response limitation of the Amgen drug and...
Today's Sponsors
Today's Sponsor